Coherus director granted RSUs and options

Coherus Oncology, Inc. reported that director Rita A. Karachun received equity compensation on June 5, 2026.

Rhea-AI Filing Summary

Coherus Oncology, Inc. reported that director Rita A. Karachun received equity compensation on June 5, 2026. She was granted 30,000 restricted stock units (RSUs), each convertible into one share of common stock upon vesting, with 100% of the RSUs vesting on the one year anniversary of June 3, 2026, subject to her continued service. She was also granted a stock option for 60,000 shares of common stock at an exercise price of $1.45 per share, which vests and becomes exercisable in full on June 3, 2027, subject to continued service. Following these awards, she holds 30,000 shares of common stock and 60,000 stock options directly.

Insider Trade Summary

Grant/Award: 90,000 shares

Grant/Award 2 txns

Insider Karachun Rita A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	60,000	$0.00	$0.00
Grant/Award	Common Stock	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 60,000 contracts (Direct); Common Stock — 30,000 shares (Direct)

Footnotes (2)

1. F1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
2. F2. The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.

Key Figures

RSU grant: 30,000 RSUs RSU vesting date reference: One year anniversary of June 3, 2026 Stock option grant: 60,000 options +4 more

7 metrics

RSU grant 30,000 RSUs Grant to director Rita A. Karachun on June 5, 2026

RSU vesting date reference One year anniversary of June 3, 2026 100% of RSUs vest on this date, subject to continued service

Stock option grant 60,000 options Grant to purchase Coherus common stock

Option exercise price $1.45 per share Exercise price for 60,000 stock options

Option vesting date June 3, 2027 Options vest and become exercisable in full on this date

Shares held after grant 30,000 shares Total Coherus common shares held directly after transactions

Options held after grant 60,000 options Total stock options held directly after transactions

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy), exercise price, vesting

4 terms

restricted stock units ("RSUs") financial

"Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with an exercise price of 1.4500"

exercise price financial

"conversion_or_exercise_price": "1.4500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"100% of the RSUs shall vest on the one year anniversary of June 3, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Rita A. Karachun receive from Coherus (CHRS)?

Rita A. Karachun received 30,000 restricted stock units and a stock option for 60,000 shares. The option has a $1.45 exercise price and both awards are subject to future vesting and her continued service with Coherus Oncology, Inc.

When do Rita A. Karachun’s Coherus (CHRS) RSUs vest?

All 30,000 RSUs granted to Rita A. Karachun vest on the one year anniversary of June 3, 2026. Vesting is contingent on her maintaining a continued service relationship with Coherus Oncology, Inc. through that vesting date under the award terms.

What are the terms of Rita A. Karachun’s Coherus (CHRS) stock options?

She received a stock option covering 60,000 shares of Coherus common stock at a $1.45 exercise price. The underlying shares vest and become exercisable as to 100% of the total on June 3, 2027, subject to her continued service relationship with the company.

How many Coherus (CHRS) shares does Rita A. Karachun hold after these grants?

After the reported transactions, she holds 30,000 shares of Coherus common stock and 60,000 stock options directly. The options are not yet exercisable and will only become exercisable in full on June 3, 2027 under the vesting schedule disclosed.

Is Rita A. Karachun’s Coherus (CHRS) Form 4 a stock purchase or compensation grant?

The Form 4 reflects compensation-related equity grants rather than an open-market stock purchase. She received 30,000 RSUs and 60,000 stock options at a $1.45 exercise price, both subject to future vesting based on her continued service with Coherus Oncology, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 06:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Karachun Rita A

(Last) (First) (Middle)

C/O COHERUS ONCOLOGY, INC.

333 TWIN DOLPHIN DRIVE, SUITE 600

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Coherus Oncology, Inc. [ CHRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		30,000(1)	A	$0	30,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.45	06/05/2026		A		60,000		(2)	06/05/2036	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.

2. The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.

	/s/ Bryan McMichael, as Attorney-in-Fact for Rita A. Karachun	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)